Seemay Chou, a computational biologist and philanthropist, has launched Radial, a nonprofit organization backed by approximately $3.5 billion in committed funding, with the stated objective of reshaping how scientific research is conceived, funded, and executed in the era of artificial intelligence. The initiative represents one of the more substantial private commitments to basic science infrastructure in recent memory, and its early programmatic priorities suggest a particular focus on the data ecosystems that underpin modern AI-driven discovery.

Chou and her partner have directed the funds toward what Radial describes as bold, high-risk scientific projects that conventional grant-making institutions have historically been reluctant to support. The organization operates on the premise that transformative scientific progress is often stalled not by a lack of talent or curiosity, but by funding mechanisms that reward incremental work and penalize ambiguity. Radial positions itself as a corrective to that tendency.

Among the initiative’s first major projects is an effort called Diffuse, which seeks to construct a next-generation structural biology database. The ambition behind Diffuse is considerable: investigators involved in the project are attempting to build the kind of comprehensive, computationally accessible data resource that, by analogy, gave rise to AlphaFold, the DeepMind-developed protein structure prediction system that transformed structural biology and earned its principal architects the 2024 Nobel Prize in Chemistry. AlphaFold’s success depended in no small part on the Protein Data Bank, a decades-old repository of experimentally determined protein structures. Diffuse is designed to serve a similar foundational role for the next wave of AI systems aimed at biological problems.

The rationale is straightforward, if not simple to execute. AI models in medicine and biology are only as capable as the data on which they are trained. When those underlying datasets are incomplete, biased, or poorly curated, the models that emerge from them inherit those deficiencies. Structural biology databases, in particular, have grown in both size and importance as researchers attempt to move from predicting protein shapes to understanding molecular function, drug binding behavior, and disease mechanisms at the atomic level. A more comprehensive and rigorously annotated resource would, in theory, allow future AI systems to make predictions with greater accuracy and broader applicability.

The clinical implications of this kind of infrastructure work are not immediately visible in the way that a phase III trial result or a device approval is. Database construction does not generate headlines. It generates the conditions under which headlines eventually become possible. The history of biomedical AI is populated with examples of this dynamic: the genomic databases assembled through years of painstaking effort eventually enabled polygenic risk score research and pharmacogenomics applications that are now entering clinical practice. Structural databases occupy an analogous position in the drug discovery pipeline.

Chou’s background is in biochemistry and structural biology, and she previously served as a principal investigator at the Chan Zuckerberg Biohub, a research organization in San Francisco that similarly attempts to fund science at the boundary between basic discovery and translational application. Her experience within that institution appears to have shaped Radial’s operating philosophy. The organization is explicitly not structured as a traditional grant-making body that reviews proposals and disburses funds on a fixed cycle. Instead, Radial describes itself as actively co-designing research programs with scientists, taking a more hands-on role in shaping the questions being asked and the methods being applied.

That posture carries both advantages and risks. On the favorable side, it allows the organization to respond to emerging scientific opportunities more rapidly than a traditional funding body might. It also permits a kind of intellectual coherence across projects that fragmented, investigator-initiated grant portfolios rarely achieve. On the less favorable side, it concentrates considerable scientific judgment in a small leadership team and raises questions about how dissenting perspectives or unconventional approaches will be incorporated when they diverge from the organization’s central priorities.

These are not new tensions in private science philanthropy. The Howard Hughes Medical Institute, the Wellcome Trust, and the Chan Zuckerberg Initiative have all navigated some version of the same tradeoff between directed programmatic funding and the open-ended curiosity-driven inquiry that has historically produced some of biology’s most consequential discoveries. Radial’s early emphasis on AI infrastructure suggests a strong prior belief that the next major advances will emerge from computational methods applied to high-quality data, rather than from purely experimental approaches. Whether that prior is well-calibrated will not be clear for years.

The timing of Radial’s launch is notable. Federal funding for basic science has faced persistent uncertainty in the United States over the past several years, and the research community has grown increasingly attentive to the role that private philanthropy plays in filling gaps left by fluctuating public investment. The National Institutes of Health budget, while substantial, is subject to congressional appropriation cycles and political pressures that can disrupt multi-year research programs. Private organizations with large endowments and long time horizons can in principle make commitments that federal agencies cannot, particularly for high-risk work with uncertain near-term payoffs.

At the same time, the concentration of scientific agenda-setting power in a small number of wealthy individuals and the organizations they control has attracted scrutiny from within the research community. Critics have noted that philanthropic science funding, however well-intentioned, reflects the priorities and blind spots of its donors as much as the priorities of the broader scientific enterprise. The diseases and populations that receive attention tend to correlate with the interests of funders, not always with the global burden of illness. Radial has not yet published a comprehensive statement of its research priorities beyond the initial emphasis on AI and structural biology, and it is too early to assess whether its portfolio will reflect a broad or narrow conception of biomedical need.

For clinicians and clinical researchers in Hawaii and across the Pacific, the relevance of Radial’s work may not be immediately apparent. Structural biology databases and AI model training pipelines are several steps removed from bedside practice. The connection becomes more direct when one considers the downstream applications: improved protein structure prediction tools accelerate drug discovery; better AI models for molecular function enable more precise identification of disease mechanisms; richer biological databases support the development of diagnostics and therapeutic targets that eventually reach patients.

The cardiovascular applications of structural AI are particularly worth noting. Protein misfolding diseases, including transthyretin amyloid cardiomyopathy, have become a focus of both structural biology and AI-assisted drug discovery in recent years. The availability of high-quality structural data on transthyretin and related proteins contributed to the development of stabilizer therapies now in clinical use. More comprehensive and dynamic structural databases of the kind Diffuse is attempting to build could support the next generation of targeted therapies for cardiac conditions with strong genetic and proteomic components.

Whether Radial and Diffuse ultimately deliver on their stated ambitions will depend on execution across a long and uncertain timeline. Building a scientific database of the quality and comprehensiveness required to train transformative AI systems is a project measured in years or decades, not months. It requires sustained coordination among experimental biologists, computational scientists, data curators, and software engineers. It requires buy-in from the broader research community, whose members must be willing to contribute data, validate outputs, and build tools on top of the resulting infrastructure. It requires governance structures that can maintain data quality and accessibility as the project scales.

None of these requirements is beyond reach for an organization with $3.5 billion at its disposal and leadership with deep familiarity with both academic biology and large-scale scientific coordination. But the history of ambitious science infrastructure projects is mixed, and enthusiasm at launch does not guarantee coherence at scale.

Chou has, by most accounts, identified a genuine gap. The scientific community’s capacity to generate biological data has outpaced its capacity to organize, curate, and make that data accessible in forms that AI systems can use productively. Bridging that gap is unglamorous work. It does not produce the kind of results that translate cleanly into press releases or funding narratives. It is, however, the kind of work without which the more visible advances in biomedical AI will continue to rest on foundations that are thinner than they appear.

Radial’s willingness to take on that work, backed by resources sufficient to sustain it across a realistic timeline, represents a development of consequence for the field, even if the full measure of its contribution will not be assessable for some time.